Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus CONEXXENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus CONEXXENCE.
BALZIVA-28 vs CONEXXENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Renal: 70% unchanged; fecal: 30% (including metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive